PET imaging, particularly with innovative tracers like [68Ga]-PSMA for prostate cancer and [18F]-FES for breast cancer, has demonstrated superior sensitivity and specificity due to its ability to target precise molecular processes [81]. This evidence concerns the gene FOLH1 and prostate carcinoma.